M170 Next Generation Impactor
The effort involved in the operation of cascade impactors and the uncertainty in the particle size distribution results have long been a source of concern for those involved in the testing of pharmaceutical inhalers. For this reason, in 1997, a group of prominent pharmaceutical companies involved in the development and manufacture of inhalers asked MSP to develop a new impactor specifically designed for testing pharmaceutical…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
This is an improvement on previous cascade impactor. It's used to determine particle size and final resting place for inhalation compounds.
Review Date: 3 Nov 2011 | MSP Corporation
The effort involved in the operation of cascade impactors and the uncertainty in the particle size distribution results have long been a source of concern for those involved in the testing of pharmaceutical inhalers. For this reason, in 1997, a group of prominent pharmaceutical companies involved in the development and manufacture of inhalers asked MSP to develop a new impactor specifically designed for testing pharmaceutical inhalers using the very latest design theory. The result, the Next Generation Impactor (NGI), was launched in 2000.
The NGI is a high-performance, precision, particle classifying cascade impactor designed for testing MDIs, DPIs, nebulizers and aerosol and nasal sprays. Calibrations to document the stage cut-off aerodynamic diameters at 15, 30, 60 and 100 L/min were conducted according to pharmaceutical standards. The NGI has seven stages plus a micro-orifice collector (MOC) and its main features include:
- Designed by and for the pharma industry
- Meets and exceeds all USP and EP specifications
- State of the art aerodynamic performance
- Operates at any flow rate between 15 and 100 L/min
- Particle size range covered: 0.24 to 11.7 microns (dependent on flow rate)
- 7 stages total with 5 stages always in the cut-off range between 0.54 and 6.12 microns
- Corrosion resistant construction
- Electrically conductive; unaffected by static
- Excellent accuracy, reproducibility and stage efficiency: all stages 500 < Re < 3000
- Easy drug recovery with low inter-stage losses
- Comprised of just 3 main parts to lend itself to practical semi and full automation
- Monographs incorporated both into the USP and EP
Today, its accuracy, ease of use and high productivity is making the NGI the new “workhorse” of the pharmaceutical industry.
